Faculty Collaboration Database

CTSI Cores Search Research Informatics REDCap

Samantha M. Jaglowski MD, MPH

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Center for International Blood and Marrow Transplant Research (CIBMTR)

Send Message

Request Meeting

View Curriculum Vitae

Publications (123)

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. (Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA) J Clin Oncol 2024 Mar 29:JCO2400033 PMID: 38552193 03/29/2024

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. (Magenau J, Jaglowski S, Uberti J, Farag SS, Riwes MM, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang MJ, Burns LJ, Liu Y, Zheng P, Reddy P) Blood 2024 Jan 04;143(1):21-31 PMID: 37647633 PMCID: PMC10934299 SCOPUS ID: 2-s2.0-85173140340 08/30/2023 1 Citation

Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability. (Ho VT, Klumpp TR, Liang WH, Prestegaard M, Horwitz M, Hamilton BK, Page K, Jaglowski S, Huber J, Martinez C, Shenoy V, Chen A, Rizzo D) Transplant Cell Ther 2023 Sep;29(9):539-547 PMID: 37379969 SCOPUS ID: 2-s2.0-85165030784 06/29/2023

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor. (Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski S, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Grossman BJ, Westervelt P, DiPersio JF, Uy GL) Blood Adv 2023 Sep 26;7(18):5210-5214 PMID: 37327120 PMCID: PMC10500469 SCOPUS ID: 2-s2.0-85168310441 06/16/2023 3 Citations

Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracil. (Gray AN, Avila C, Chung CG, Seminario-Vidal L, Mims A, Dulmage B, Larkin K, Choe H, Jaglowski S, Vasu S, Kaffenberger BH) JAAD Case Rep 2023 Jun;36:82-88 PMID: 37250015 PMCID: PMC10220457 SCOPUS ID: 2-s2.0-85160098590 05/30/2023

A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. (Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L) Cancers (Basel) 2023 Feb 24;15(5) PMID: 36900230 PMCID: PMC10000669 SCOPUS ID: 2-s2.0-85149827159 03/12/2023 4 Citations

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. (Chakraborty R, Yi J, Rybicki L, Preussler J, Deol A, Loren A, Savani B, Jim HSL, Cerny J, Reynolds J, Whitten J, Wingard JR, McGuirk JP, Uberti J, Khera N, Stiff P, Jaglowski SM, Hashmi S, Holtan SG, Devine S, Hahn T, Whalen VL, Saber W, Wood W, Baker KS, Syrjala K, Majhail NS) Transplant Cell Ther 2023 Jun;29(6):388.e1-388.e6 PMID: 36870388 PMCID: PMC10718487 SCOPUS ID: 2-s2.0-85153345405 03/05/2023 1 Citation

Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine. (Himed S, Chung C, Dulmage B, Jaglowski S, Bond D, Maddocks K, Kaffenberger BH) J Eur Acad Dermatol Venereol 2023 Jul;37(7):e890-e893 PMID: 36800311 SCOPUS ID: 2-s2.0-85149399595 02/18/2023

A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. (Shouse G, Kaempf A, Gordon MJ, Artz A, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV) Blood Adv 2023 Jul 25;7(14):3516-3529 PMID: 36735393 PMCID: PMC10362276 SCOPUS ID: 2-s2.0-85158873555 02/04/2023 13 Citations

Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. (Faisal MS, Hanel W, Voorhees T, Li R, Huang Y, Khan A, Bond D, Sawalha Y, Reneau J, Alinari L, Baiocchi R, Christian B, Maddocks K, Efebera Y, Penza S, Saad A, Brammer J, DeLima M, Jaglowski S, Epperla N) Cancer Med 2023 Apr;12(7):8228-8237 PMID: 36653918 PMCID: PMC10134314 SCOPUS ID: 2-s2.0-85146949278 01/20/2023

Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience. (Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N) Cancers (Basel) 2022 Nov 14;14(22) PMID: 36428678 PMCID: PMC9688916 SCOPUS ID: 2-s2.0-85142508230 11/27/2022 1 Citation

Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors. (Hong S, Zhao J, Wang S, Wang H, Lee JH, Farhadfar N, McGuirk JP, Savani BN, Shahrukh HK, Stiff P, Khera N, Hahn T, Loren AW, Jaglowski SM, Wood WA, Saber W, Cerny J, Holtan SG, Reynolds JM, Deol A, Jim H, Uberti J, Whalen V, Yi JC, Preussler J, Baker KS, Shaw BE, Devine S, Syrjala K, Majhail NS, Wingard JR, Al-Mansour Z) Transplant Cell Ther 2023 Mar;29(3):202.e1-202.e8 PMID: 36427784 PMCID: PMC10165614 SCOPUS ID: 2-s2.0-85146977106 11/26/2022

Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem. (Koo J, Auletta JJ, Hartley DM, Huber J, Jaglowski S, Kapadia M, Kusnier K, Lehmann L, Maakaron J, Myers KC, Pai A, Parker L, Phelan R, Sper C, Rotz SJ, Dandoy CE) Transplant Cell Ther 2022 Nov;28(11):737-746 PMID: 35902050 PMCID: PMC9313529 SCOPUS ID: 2-s2.0-85136675259 07/29/2022 3 Citations

Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation. (Rotz SJ, Yi JC, Hamilton BK, Wei W, Preussler JM, Cerny J, Deol A, Jim H, Khera N, Hahn T, Hashmi SK, Holtan S, Jaglowski SM, Loren AW, McGuirk J, Reynolds J, Saber W, Savani BN, Stiff P, Uberti J, Wingard JR, Wood WA, Baker KS, Majhail NS, Syrjala KL) Transplant Cell Ther 2022 Oct;28(10):701.e1-701.e7 PMID: 35872304 PMCID: PMC9547939 SCOPUS ID: 2-s2.0-85136307766 07/26/2022 4 Citations

Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. (Sigmund AM, Huang Y, Ruppert AS, Maddocks K, Rogers KA, Jaglowski S, Bhat SA, Kittai AS, Grever MR, Byrd JC, Woyach JA) Leukemia 2022 Aug;36(8):2129-2131 PMID: 35842461 SCOPUS ID: 2-s2.0-85134414656 07/17/2022 3 Citations

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. (Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, Dorritie K, Jaglowski S, Radford J, Morschhauser F, Cunningham D, Martin Garcia-Sancho A, Tzachanis D, Ulrickson ML, Karmali R, Kekre N, Thieblemont C, Enblad G, Dreger P, Malladi R, Joshi N, Wang WJ, Solem CT, Snider JT, Cheng P, To C, Kersten MJ) Blood 2022 Nov 24;140(21):2248-2260 PMID: 35839452 PMCID: PMC10653042 SCOPUS ID: 2-s2.0-85135288210 07/16/2022 20 Citations

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. (Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF) Haematologica 2023 Jan 01;108(1):98-109 PMID: 35833303 PMCID: PMC9827150 SCOPUS ID: 2-s2.0-85144275501 07/15/2022 30 Citations

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. (Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, He F, Maziarz RT, Mayer S, Makita S, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni C, Bishop MR) Blood Adv 2022 Aug 23;6(16):4816-4820 PMID: 35687492 PMCID: PMC9631665 SCOPUS ID: 2-s2.0-85136465627 06/11/2022 2 Citations

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. (Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM) J Clin Oncol 2023 Jan 20;41(3):555-567 PMID: 35658525 PMCID: PMC9870225 SCOPUS ID: 2-s2.0-85133881567 06/07/2022 92 Citations

Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. (Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A, Hamadani M) Transplant Cell Ther 2022 Aug;28(8):487.e1-487.e7 PMID: 35609865 PMCID: PMC9375438 SCOPUS ID: 2-s2.0-85132887608 05/25/2022 4 Citations

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. (Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA) Clin Cancer Res 2022 Aug 02;28(15):3242-3247 PMID: 35608822 PMCID: PMC9364840 SCOPUS ID: 2-s2.0-85135596906 05/25/2022 14 Citations

Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant. (Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N) Front Oncol 2022;12:801879 PMID: 35280722 PMCID: PMC8913574 SCOPUS ID: 2-s2.0-85126180582 03/15/2022 5 Citations

Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma. (Sigmund AM, Denlinger N, Huang Y, Bond D, Voorhees T, Bajwa A, Elder P, Brammer JE, Saad A, Penza S, Vasu S, de Lima M, Jaglowski S, Kittai AS) Transplant Cell Ther 2022 Jun;28(6):342.e1-342.e5 PMID: 35248778 PMCID: PMC9284421 SCOPUS ID: 2-s2.0-85128315889 03/07/2022 7 Citations

Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes. (Kapadia M, Lehmann L, Auletta J, Beatty L, Bhatt N, Blacken R, Demmel K, Dodd T, Desmond C, Fitch T, Flesch L, Hartley D, Huber J, Ingraham H, Jakubowski R, Klunk A, Krupski C, Kusnier K, Liberio N, Maakaron J, Mueller M, Myers KC, Pai A, Parker L, Patel S, Phelan R, Polishchuk V, Sigmund A, Sper C, Tarquini S, Juckett M, Jaglowski S, Dandoy C, Rotz S) Transplant Cell Ther 2022 May;28(5):233-241 PMID: 35151937 SCOPUS ID: 2-s2.0-85126771134 02/14/2022 5 Citations

A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. (Bond DA, Huang Y, Christian BA, Jaglowski S, Benson D, Alinari L, Baiocchi RA, Cohen JB, Blum KA, Maddocks KJ) Leuk Lymphoma 2022 Jul;63(7):1750-1753 PMID: 35129029 SCOPUS ID: 2-s2.0-85124363293 02/08/2022 1 Citation

Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma. (Bajwa A, Huang Y, Li R, Denlinger N, Brammer J, Penza S, Saad A, Jaglowski S, Kittai AS) Leuk Lymphoma 2022 Jun;63(6):1492-1495 PMID: 35109749 PMCID: PMC9284420 SCOPUS ID: 2-s2.0-85124291905 02/04/2022

CAR T-cell therapy for B-cell lymphoma. (Denlinger N, Bond D, Jaglowski S) Curr Probl Cancer 2022 Feb;46(1):100826 PMID: 35012754 PMCID: PMC9284423 SCOPUS ID: 2-s2.0-85119250641 01/12/2022 10 Citations

Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults. (Vasu S, Bostic M, Zhao Q, Sharma N, Puto M, Knight S, Scott D, Guzman R, Kromer M, Tackett K, Lind K, Knill K, Watson E, Wall S, Saad A, Choe H, Larkin K, Brammer J, Jaglowski S, Penza S, Davies SM, Cataland S) Blood Adv 2022 Feb 22;6(4):1342-1349 PMID: 34932790 PMCID: PMC8864665 SCOPUS ID: 2-s2.0-85125382933 12/22/2021 6 Citations

Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience. (Schaefer A, Huang Y, Kittai A, Maakaron JE, Saygin C, Brammer J, Penza S, Saad A, Jaglowski SM, William BM) Cancer Manag Res 2021;13:8901-8906 PMID: 34876852 PMCID: PMC8643129 SCOPUS ID: 2-s2.0-85120439274 12/09/2021 14 Citations

Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. (Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N) Hematol Oncol 2022 Feb;40(1):48-56 PMID: 34763367 SCOPUS ID: 2-s2.0-85119403860 11/12/2021 2 Citations

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. (Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT) Lancet Oncol 2021 Oct;22(10):1403-1415 PMID: 34516954 SCOPUS ID: 2-s2.0-85115754295 09/14/2021 227 Citations

Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. (Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M) Blood Adv 2021 Sep 28;5(18):3528-3539 PMID: 34496026 PMCID: PMC8945575 SCOPUS ID: 2-s2.0-85116143497 09/09/2021 23 Citations

Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. (Chin KK, Kim HT, Inyang EA, Ho V, Koreth J, Romee R, Gooptu M, Shapiro R, Antin J, Soiffer R, Jaglowski S, Pidala J, Cutler C) Transplant Cell Ther 2021 Dec;27(12):990.e1-990.e7 PMID: 34481113 SCOPUS ID: 2-s2.0-85116767565 09/05/2021 19 Citations

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. (Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, William BM, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D) J Immunother Cancer 2021 Aug;9(8) PMID: 34429331 PMCID: PMC8386216 SCOPUS ID: 2-s2.0-85113782193 08/26/2021 18 Citations

Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists. (Nusbaum KB, Dulmage B, Choi JN, Jaglowski SM, Korman AM) J Am Acad Dermatol 2022 Sep;87(3):597-604 PMID: 34293386 SCOPUS ID: 2-s2.0-85111563810 07/23/2021 6 Citations

Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation. (Sharma N, Faisal MS, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims AS, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Sigmund AM, Efebera YA) J Clin Med 2021 Jun 27;10(13) PMID: 34199028 PMCID: PMC8268935 SCOPUS ID: 2-s2.0-85114075754 07/03/2021 2 Citations

Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. (Miller CR, Huang Y, Ruppert AS, Labanowska J, Jaglowski SM, Maddocks KJ, Rogers KA, Bhat S, Kittai AS, Grever M, Lapalombella R, Abruzzo LV, Heerema NA, Byrd JC, Hertlein EK, Woyach JA) Leukemia 2021 Nov;35(11):3287-3290 PMID: 33820961 PMCID: PMC8490482 SCOPUS ID: 2-s2.0-85103562051 04/07/2021 1 Citation

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. (Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C) Leukemia 2021 Sep;35(9):2672-2683 PMID: 33658659 SCOPUS ID: 2-s2.0-85102037379 03/05/2021 47 Citations

Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation. (Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, Rosko A, Chaudhry M, Devarakonda S, Bumma N, Khan A, Vasu S, Jaglowski S, William BM, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y) Cancers (Basel) 2021 Feb 04;13(4) PMID: 33557088 PMCID: PMC7913846 SCOPUS ID: 2-s2.0-85100344014 02/10/2021 7 Citations

Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS. (Rasor B, Dickerson T, Zhao Q, Elder P, Brammer JE, Larkin K, Jaglowski S, Mims A, Penza S, Vasu S, Wall SA, William B, Saad A, Roddy JVF, Choe H, Puto M) Leuk Lymphoma 2021 Apr;62(4):944-951 PMID: 33231122 PMCID: PMC8012251 SCOPUS ID: 2-s2.0-85096596445 11/25/2020 3 Citations

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. (Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S) Blood Adv 2020 Nov 10;4(21):5414-5424 PMID: 33147337 PMCID: PMC7656920 SCOPUS ID: 2-s2.0-85096931359 11/05/2020 256 Citations

Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. (Grana A, Gut N, Williams K, Maakaron J, Porter K, William BM, Vasu S, Penza S, Brammer JE, Saad A, Puto M, Jaglowski SM, Roddy J) Clin Lymphoma Myeloma Leuk 2021 Apr;21(4):238-245 PMID: 33132101 SCOPUS ID: 2-s2.0-85094605341 11/03/2020 8 Citations

Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. (Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B, Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM) Blood Adv 2020 Oct 13;4(19):4648-4652 PMID: 33002129 PMCID: PMC7556158 SCOPUS ID: 2-s2.0-85092369159 10/02/2020 53 Citations

Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. (Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV) Transplant Cell Ther 2021 Jan;27(1):46-52 PMID: 33002640 SCOPUS ID: 2-s2.0-85095565490 10/02/2020 28 Citations

A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. (DeFilipp Z, Burns LJ, Jaglowski SM, Leppin AL, Pavletic S, Waldman B, Weisdorf DJ, Wood WA, Khera N) Biol Blood Marrow Transplant 2020 Dec;26(12):e305-e308 PMID: 32920205 PMCID: PMC7735536 SCOPUS ID: 2-s2.0-85092101705 09/14/2020 5 Citations

Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. (Jaggers JL, Giri S, Klepin HD, Wildes TM, Olin RL, Artz A, Wall S, Jaglowski S, William B, Benson DM, Rosko AE) J Geriatr Oncol 2021 Mar;12(2):235-238 PMID: 32855108 SCOPUS ID: 2-s2.0-85089825957 08/29/2020 9 Citations

A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. (Shea L, Watkins MP, Wan F, Cashen AF, Wagner-Johnston ND, Jacoby MA, Abboud CN, Dipersio JF, Hurd DD, Jaglowski SM, Bartlett NL, Fehniger TA) Biol Blood Marrow Transplant 2020 Dec;26(12):2223-2228 PMID: 32829079 PMCID: PMC8212249 SCOPUS ID: 2-s2.0-85091204107 08/24/2020 3 Citations

Second cancer incidence in CLL patients receiving BTK inhibitors. (Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM, Rogers KA, Bhat SA, Grever MR, Jaglowski SM, Maddocks KJ, Byrd JC, Woyach JA) Leukemia 2020 Dec;34(12):3197-3205 PMID: 32704159 PMCID: PMC7688551 SCOPUS ID: 2-s2.0-85088523767 07/25/2020 39 Citations

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. (Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH) J Clin Oncol 2020 Sep 20;38(27):3095-3106 PMID: 32667831 PMCID: PMC7499617 SCOPUS ID: 2-s2.0-85091191289 07/16/2020 209 Citations

Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. (Ardura M, Hartley D, Dandoy C, Lehmann L, Jaglowski S, Auletta JJ, Transplant-Associated Learning Network Team (TALNT)) Biol Blood Marrow Transplant 2020 Jul;26(7):e147-e160 PMID: 32339662 PMCID: PMC7194714 SCOPUS ID: 2-s2.0-85084139088 04/28/2020 31 Citations

Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look. (Maakaron JE, Liscynesky C, Boghdadly ZE, Huang Y, Agyeman A, Brammer J, Penza S, Efebera Y, Benson D, Rosko A, William B, Jaglowski SM) Biol Blood Marrow Transplant 2020 Aug;26(8):e198-e201 PMID: 32304873 SCOPUS ID: 2-s2.0-85085043179 04/19/2020 7 Citations

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. (Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM) N Engl J Med 2020 Apr 02;382(14):1331-1342 PMID: 32242358 PMCID: PMC7731441 SCOPUS ID: 2-s2.0-85082856912 04/04/2020 1047 Citations

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. (Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS) Blood Adv 2020 Feb 25;4(4):629-637 PMID: 32074277 PMCID: PMC7042998 SCOPUS ID: 2-s2.0-85082194867 02/20/2020 50 Citations

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. (Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak Ö, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK) Blood Adv 2020 Feb 11;4(3):560-572 PMID: 32045475 PMCID: PMC7013261 SCOPUS ID: 2-s2.0-85082188780 02/12/2020 85 Citations

Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial. (Pidala J, Jaglowski S, Im A, Chen G, Onstad L, Storer B, Kurukulasuriya C, Lee SJ) Biol Blood Marrow Transplant 2020 Feb;26(2):278-284 PMID: 31499215 SCOPUS ID: 2-s2.0-85074078243 09/10/2019 9 Citations

Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. (Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, Flowers MED, Logan AC, Nakamura R, Chang S, Clow F, Lal ID, Styles L, Jaglowski S) Biol Blood Marrow Transplant 2019 Oct;25(10):2002-2007 PMID: 31260802 SCOPUS ID: 2-s2.0-85069680091 07/02/2019 65 Citations

Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. (Issa H, Sharma N, Zhao Q, Ruppert AS, Elder P, Benson DM, Penza S, Vasu S, William B, Jaglowski S, Devine SM, Efebera YA) Biol Blood Marrow Transplant 2019 Oct;25(10):1993-2001 PMID: 31229641 SCOPUS ID: 2-s2.0-85068851687 06/24/2019 8 Citations

Have We Achieved a Goldilocks Grade of Graft-Versus-Host Disease? (Vasu S, Jaglowski S) Biol Blood Marrow Transplant 2019 Jun;25(6):e189-e190 PMID: 31002995 SCOPUS ID: 2-s2.0-85065993096 04/20/2019

Running the tank to empty: how far can the CAR go? (Vasu S, Jaglowski SM) Blood 2019 Apr 11;133(15):1617-1618 PMID: 30975642 SCOPUS ID: 2-s2.0-85064836483 04/13/2019 1 Citation

Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. (Yucebay F, Matthews C, Puto M, Li J, William B, Jaglowski SM, Penza SL, Vasu S, Benson DM, Andritsos LA, Devine SM, Efebera YA, Roddy JVF) Leuk Lymphoma 2019 Sep;60(9):2223-2229 PMID: 30764681 SCOPUS ID: 2-s2.0-85061930316 02/16/2019 15 Citations

BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. (Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA) Bone Marrow Transplant 2019 Oct;54(10):1553-1561 PMID: 30718797 SCOPUS ID: 2-s2.0-85061046839 02/06/2019 8 Citations

BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. (Singer S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA) Biol Blood Marrow Transplant 2019 Jun;25(6):1107-1115 PMID: 30716453 SCOPUS ID: 2-s2.0-85062607809 02/05/2019 9 Citations

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT, JULIET Investigators) N Engl J Med 2019 Jan 03;380(1):45-56 PMID: 30501490 SCOPUS ID: 2-s2.0-85058995720 12/07/2018 2481 Citations

Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease? (Vaughn JL, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, William B, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Benson D, Devine S, Cataland S, Vasu S) Bone Marrow Transplant 2019 Jun;54(6):913-916 PMID: 30413812 SCOPUS ID: 2-s2.0-85056320211 11/11/2018 2 Citations

Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. (Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, Yang S, Wu H, Bostic M, Jaglowski S, Brammer JE, William B, Choe H, Mims AS, Penza S, Efebera Y, Devine S, Cataland S, Davies SM, Vasu S) Blood Adv 2018 Oct 23;2(20):2619-2628 PMID: 30327370 PMCID: PMC6199668 SCOPUS ID: 2-s2.0-85072254595 10/18/2018 47 Citations

How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. (Jaglowski SM, Blazar BR) Blood Adv 2018 Aug 14;2(15):2012-2019 PMID: 30108109 PMCID: PMC6093735 SCOPUS ID: 2-s2.0-85064263865 08/16/2018 66 Citations

Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. (Rosko AE, Huang Y, Benson DM, Efebera YA, Hofmeister C, Jaglowski S, Devine S, Bhatt G, Wildes TM, Dyko A, Jones D, Naughton MJ, Byrd JC, Burd CE) J Geriatr Oncol 2019 May;10(3):479-485 PMID: 29983352 PMCID: PMC6320732 SCOPUS ID: 2-s2.0-85049441525 07/10/2018 57 Citations

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. (O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE) JAMA Oncol 2018 May 01;4(5):712-716 PMID: 29470582 PMCID: PMC5885180 SCOPUS ID: 2-s2.0-85047476253 02/23/2018 18 Citations

Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. (Richardson DR, Huang Y, McGinty HL, Elder P, Newlin J, Kirkendall C, Andritsos L, Benson D, Blum W, Efebera Y, Penza S, Hofmeister C, Jaglowski S, Klisovic R, Vasu S, William B, Devine S, Rosko AE) Bone Marrow Transplant 2018 Nov;53(11):1418-1427 PMID: 29445123 PMCID: PMC6092254 SCOPUS ID: 2-s2.0-85042124051 02/16/2018 17 Citations

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. (Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, Lozanski G, Zhao W, Gordon AL, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Blum KA, T Awan F, Rogers KA, Grever MR, Johnson AJ, Abruzzo LV, Hertlein EK, Blachly JS, Woyach JA, Byrd JC) Blood Adv 2017 Aug 22;1(19):1584-1588 PMID: 29296799 PMCID: PMC5728464 SCOPUS ID: 2-s2.0-85044444784 01/04/2018 36 Citations

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. (Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT) Blood Adv 2017 Sep 12;1(20):1739-1748 PMID: 29296820 PMCID: PMC5728342 SCOPUS ID: 2-s2.0-85034042514 01/04/2018 114 Citations

Road trip to remission with CARs. (Jaglowski SM) Blood 2017 Nov 23;130(21):2240 PMID: 29170193 SCOPUS ID: 2-s2.0-85034814994 11/25/2017

Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. (Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P) Cancer 2018 Feb 15;124(4):816-825 PMID: 29125192 PMCID: PMC5871233 SCOPUS ID: 2-s2.0-85033592450 11/11/2017 44 Citations

Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. (Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2018 Jan;24(1):78-85 PMID: 29032272 PMCID: PMC5743624 SCOPUS ID: 2-s2.0-85034849252 10/17/2017 8 Citations

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. (Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S) Blood 2017 Nov 23;130(21):2243-2250 PMID: 28924018 PMCID: PMC6033048 SCOPUS ID: 2-s2.0-85034862360 09/20/2017 321 Citations

A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. (Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA) Clin Lymphoma Myeloma Leuk 2017 Jun;17(6):347-353 PMID: 28622959 PMCID: PMC6033275 SCOPUS ID: 2-s2.0-85020740127 06/18/2017 23 Citations

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. (Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M) J Hematol Oncol 2017 Jun 12;10(1):117 PMID: 28606176 PMCID: PMC5469142 SCOPUS ID: 2-s2.0-85020468882 06/14/2017 18 Citations

BTK^C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. (Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC) J Clin Oncol 2017 May 01;35(13):1437-1443 PMID: 28418267 PMCID: PMC5455463 SCOPUS ID: 2-s2.0-85018308247 04/19/2017 350 Citations

The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. (Guinn D, Lehman A, Fabian C, Yu L, Maddocks K, Andritsos LA, Jones JA, Flynn JM, Jaglowski SM, Woyach JA, Byrd JC, Johnson AJ) Cancer Med 2017 Apr;6(4):778-787 PMID: 28299881 PMCID: PMC5387133 SCOPUS ID: 2-s2.0-85015234955 03/17/2017 14 Citations

A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma. (Cohen JB, Maddocks KJ, Huang Y, Christian BA, Jaglowski SM, Flowers CR, Blum KA) Leuk Lymphoma 2017 Sep;58(9):1-2 PMID: 28278718 PMCID: PMC5497734 SCOPUS ID: 2-s2.0-85013152251 03/11/2017 3 Citations

A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. (Haverkos BM, Huang Y, Elder P, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SM) Bone Marrow Transplant 2017 Apr;52(4):561-566 PMID: 28067870 PMCID: PMC5382040 SCOPUS ID: 2-s2.0-85008622672 01/10/2017 8 Citations

GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. (Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS) Bone Marrow Transplant 2017 Mar;52(3):400-408 PMID: 27941764 PMCID: PMC5332289 SCOPUS ID: 2-s2.0-85014524149 12/13/2016 39 Citations

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. (Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB) Blood 2016 Dec 22;128(25):2899-2908 PMID: 27802969 PMCID: PMC5179333 SCOPUS ID: 2-s2.0-85014937234 11/03/2016 62 Citations

Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668]. (Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM) Biol Blood Marrow Transplant 2016 Jul;22(7):1341 PMID: 27291293 SCOPUS ID: 2-s2.0-84975321904 06/14/2016 1 Citation

Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. (Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M) J Clin Oncol 2016 Sep 10;34(26):3141-9 PMID: 27269951 PMCID: PMC5012706 SCOPUS ID: 2-s2.0-84989838395 06/09/2016 189 Citations

Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. (Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S) Bone Marrow Transplant 2016 Sep;51(9):1241-4 PMID: 27064689 SCOPUS ID: 2-s2.0-84963621743 04/12/2016 51 Citations

Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. (Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M) Br J Haematol 2016 Jul;174(2):235-48 PMID: 26989808 PMCID: PMC4940282 SCOPUS ID: 2-s2.0-84978080661 03/19/2016 104 Citations

Ibrutinib for treatment of chronic lymphocytic leukemia. (Vela CM, McBride A, Jaglowski SM, Andritsos LA) Am J Health Syst Pharm 2016 Mar 15;73(6):367-75 PMID: 26953281 SCOPUS ID: 2-s2.0-84962754639 03/10/2016 12 Citations

Endothelial chimerism in chronic sclerotic-type chronic graft-versus-host disease (GVHD) and GVHD-associated angiomatosis. (Kaffenberger BH, Zhang E, Duncan JR, Jaglowski S, Klisovic RB, Devine SM, Wong HK, Gru AA) Br J Dermatol 2016 Oct;175(4):782-4 PMID: 26875995 SCOPUS ID: 2-s2.0-84990249837 02/16/2016 3 Citations

Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. (Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM) Biol Blood Marrow Transplant 2016 Apr;22(4):658-668 PMID: 26743340 SCOPUS ID: 2-s2.0-84960491288 01/09/2016 18 Citations

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. (Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, Flynn JM, Jaglowski SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA) Leukemia 2016 Feb;30(2):346-50 PMID: 26442611 PMCID: PMC4986508 SCOPUS ID: 2-s2.0-84959372138 10/08/2015 78 Citations

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. (Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, Miklos DB, Shulman HM, Martin PJ, Sarantopoulos S, Lee SJ, Flowers ME) Clin Cancer Res 2016 Jan 15;22(2):319-27 PMID: 26378033 PMCID: PMC4715914 SCOPUS ID: 2-s2.0-84958983532 09/18/2015 62 Citations

Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). (Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM) Biol Blood Marrow Transplant 2016 Jan;22(1):71-9 PMID: 26256940 PMCID: PMC4706501 SCOPUS ID: 2-s2.0-84952637331 08/11/2015 11 Citations

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. (Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC) Am J Hematol 2015 Nov;90(11):967-9 PMID: 26202978 PMCID: PMC7055503 SCOPUS ID: 2-s2.0-84944525401 07/24/2015 2 Citations

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. (Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA) JAMA Oncol 2015 Apr;1(1):80-7 PMID: 26182309 PMCID: PMC4520535 SCOPUS ID: 2-s2.0-84994504370 07/17/2015 478 Citations

Tocilizumab for steroid refractory acute graft-versus-host disease. (Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA) Leuk Lymphoma 2016;57(1):81-5 PMID: 26140610 PMCID: PMC4698359 SCOPUS ID: 2-s2.0-84954399184 07/04/2015 34 Citations

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. (Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC) Blood 2015 Aug 13;126(7):842-50 PMID: 26116658 PMCID: PMC4536539 SCOPUS ID: 2-s2.0-84940063235 06/28/2015 116 Citations

Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. (Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M, Center for International Blood and Marrow Transplant Research Lymphoma Working Committee) Biol Blood Marrow Transplant 2015 Sep;21(9):1605-11 PMID: 25983043 PMCID: PMC4558181 SCOPUS ID: 2-s2.0-84938993122 05/20/2015 31 Citations

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. (Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ) Blood 2015 Jul 02;126(1):61-8 PMID: 25972157 PMCID: PMC4492196 SCOPUS ID: 2-s2.0-84937841721 05/15/2015 146 Citations

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. (Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC) Leukemia 2015 Jul;29(7):1524-9 PMID: 25708835 PMCID: PMC4551390 SCOPUS ID: 2-s2.0-84937022691 02/25/2015 92 Citations

Transplant for CLL: still an option? (Jaglowski SM) Blood 2014 Dec 18;124(26):3835-6 PMID: 25525078 SCOPUS ID: 2-s2.0-84919497794 12/20/2014 1 Citation

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. (Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC) Leukemia 2015 May;29(5):1210-3 PMID: 25486872 PMCID: PMC4424166 SCOPUS ID: 2-s2.0-84929285149 12/10/2014 17 Citations

Health-related quality of life in patients who develop bronchiolitis obliterans syndrome following allo-SCT. (Amin EN, Phillips GS, Elder P, Jaglowski S, Devine SM, Wood KL) Bone Marrow Transplant 2015 Feb;50(2):289-95 PMID: 25419692 PMCID: PMC4351778 SCOPUS ID: 2-s2.0-84922405006 11/25/2014 13 Citations

A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. (Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA) Blood 2015 Jan 08;125(2):242-8 PMID: 25355819 SCOPUS ID: 2-s2.0-84920951834 10/31/2014 116 Citations

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. (Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR) J Clin Invest 2014 Nov;124(11):4867-76 PMID: 25271622 PMCID: PMC4347242 SCOPUS ID: 2-s2.0-84908656083 10/02/2014 151 Citations

A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. (Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM) Leuk Lymphoma 2015 Apr;56(4):1043-9 PMID: 25213183 PMCID: PMC4417026 SCOPUS ID: 2-s2.0-84929104919 09/13/2014 7 Citations

Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. (Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA) Leuk Lymphoma 2015 Apr;56(4):1058-65 PMID: 25166008 PMCID: PMC4417073 SCOPUS ID: 2-s2.0-84929086102 08/29/2014 15 Citations

The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. (Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LA) Bone Marrow Transplant 2014 Oct;49(10):1323-9 PMID: 25068419 PMCID: PMC4192086 SCOPUS ID: 2-s2.0-84926420359 07/30/2014 22 Citations

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. (Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC) N Engl J Med 2014 Jun 12;370(24):2286-94 PMID: 24869598 PMCID: PMC4144824 SCOPUS ID: 2-s2.0-84902183019 05/30/2014 981 Citations

Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. (Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM) Support Care Cancer 2014 Nov;22(11):2911-6 PMID: 24838259 SCOPUS ID: 2-s2.0-84919385049 05/20/2014 15 Citations

Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. (El-Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB) Biol Blood Marrow Transplant 2014 Sep;20(9):1341-8 PMID: 24813171 PMCID: PMC4127362 SCOPUS ID: 2-s2.0-84905585991 05/13/2014 45 Citations

An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor. (Haverkos BM, McBride A, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SM) Bone Marrow Transplant 2014 Aug;49(8):1052-5 PMID: 24797182 PMCID: PMC4125480 SCOPUS ID: 2-s2.0-84905699610 05/07/2014 6 Citations

Graft-versus-host disease: why have we not made more progress? (Jaglowski SM, Devine SM) Curr Opin Hematol 2014 Mar;21(2):141-7 PMID: 24468835 PMCID: PMC4131840 SCOPUS ID: 2-s2.0-84894086141 01/29/2014 36 Citations

Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. (Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC) Leukemia 2014 Jun;28(6):1365-8 PMID: 24451411 PMCID: PMC4047185 SCOPUS ID: 2-s2.0-84902073992 01/24/2014 18 Citations

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. (Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC) Blood 2013 Oct 10;122(15):2539-49 PMID: 23886836 PMCID: PMC3795457 SCOPUS ID: 2-s2.0-84888216911 07/28/2013 634 Citations

Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. (Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LA) Br J Haematol 2012 Oct;159(1):82-7 PMID: 22831395 PMCID: PMC3719859 SCOPUS ID: 2-s2.0-84866334906 07/27/2012 49 Citations

Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia. (Jaglowski SM, Byrd JC) Biol Blood Marrow Transplant 2012 Jan;18(1 Suppl):S132-8 PMID: 22226097 SCOPUS ID: 2-s2.0-84855413280 01/18/2012 9 Citations

Choosing first-line therapy for chronic lymphocytic leukemia. (Jaglowski S, Jones JA) Expert Rev Anticancer Ther 2011 Sep;11(9):1379-90 PMID: 21929312 PMCID: PMC4341916 SCOPUS ID: 2-s2.0-80053032460 09/21/2011 15 Citations

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. (Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC) Blood 2011 Jun 09;117(23):6287-96 PMID: 21422473 PMCID: PMC3122947 SCOPUS ID: 2-s2.0-79959404661 03/23/2011 664 Citations

The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. (Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC) Blood 2010 Nov 11;116(19):3705-14 PMID: 20610811 PMCID: PMC2981531 SCOPUS ID: 2-s2.0-78149474940 07/09/2010 103 Citations

Rituximab in chronic lymphocytic leukemia. (Jaglowski SM, Byrd JC) Semin Hematol 2010 Apr;47(2):156-69 PMID: 20350663 SCOPUS ID: 2-s2.0-77950324100 03/31/2010 31 Citations

Lovenox hurts. (Jaglowski SM) Ann Intern Med 2009 Oct 20;151(8):585-6 PMID: 19841460 SCOPUS ID: 2-s2.0-70350724513 10/21/2009

Lymphoma in adolescents and young adults. (Jaglowski SM, Linden E, Termuhlen AM, Flynn JM) Semin Oncol 2009 Oct;36(5):381-418 PMID: 19835736 SCOPUS ID: 2-s2.0-70349775624 10/20/2009 65 Citations

Last update: 05/17/2024

© 2024 Clinical & Translational Science Institute
Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53223

Publication and ontology data from NCBI | Disclaimer and Copyright

This site is a collaborative effort of the Medical College of Wisconsin and the Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number 2UL1TR001436) at the National Institutes of Health (NIH).

Profiles for MCW, MU, MSOE, UWM, BCW, CW, Froedtert, and VA Faculty

Samantha M. Jaglowski MD, MPH

Professor

Publications (123)